

Your commitment to quality of care is one we proudly share

That's why we created **GREAT**, the Global Registry for Endovascular Aortic Treatment, to evaluate real-world performance and inform future clinical practice.

Over a decade in the making.
Nearly 5,000 patients.
Over 30 publications.

5-YEAR TEVAR UPDATE

Evidence with real-life relevance

LARGE COHORT

578 TEVAR patients treated

with the GORE® TAG® Conformable Thoracic Endoprosthesis

LONG TERM

10-year follow-up planned

REAL-WORLD POPULATION*

44% off-label TEVAR cases¹

// GREAT provides a picture of the real-world use of [GORE® TAG® Conformable Thoracic Endoprosthesis] in TEVAR for the treatment of multiple thoracic aortic pathologies."

Ascending arch

4.5%

n = 26

Type B dissection

35.1%

n = 203

Descending thoracic aortic aneurysm

41.3%

n = 239

[See the data](#) 

* Age requirement and indication for aortic stent graft repair as determined by the treating physician.

Durable performance across thoracic dissection and aneurysmal pathologies



Through 5 years, the GORE® TAG® Conformable Thoracic Stent Graft showed sustained safety and efficacy in real-world practice.¹

GREAT outcomes at-a-glance

ZERO

Fractures
Device compressions


FAVORABLE

Freedom from all-cause mortality
Aortic-related mortality
Procedure survival 99.7%


LOW RATES¹

Stroke
Paralysis
Reintervention
Serious TYPE III endoleaks*
Migration†

All-cause mortality by pathology



Aortic-related mortality by pathology



An endovascular approach for treatment of all thoracic aortic pathologies using the [GORE® TAG® Conformable Thoracic Endoprosthesis] can be accomplished in a “real-world” setting with low peri-procedural risk and a favorable freedom from aortic-related mortality long-term through 5 years.¹

* Only serious endoleaks are reported in GREAT (i.e., those meeting the ISO141155 definition of a Serious Adverse Event).

† Only 1 device migration was seen over this time frame.

We build evidence, so you can build confidence

Designed to reflect real-world use, GREAT enriches the evidence at your disposal.

The current study reports a large cohort of thoracic pathology outcomes for TEVAR of up to 60 months. This data fills a gap of knowledge on long-term outcomes to date for this patient population over a long follow-up period, supporting ongoing use of endovascular therapy.¹

5-year analysis 

Access data 

References

1. Gable DR, Verhoeven E, Trimarchi S, *et al.*; GREAT Investigators. Endovascular treatment for thoracic aortic disease from the Global Registry for endovascular aortic treatment. *Journal of Vascular Surgery* 2024;79(5):11044-1056.e1.

 Consult Instructions
for Use
eifu.goremedical.com

INDICATIONS FOR USE IN THE U.S.: The GORE® TAG® Thoracic Stent Graft is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions in patients who have appropriate anatomy, including: adequate iliac/femoral access, aortic inner diameter in the range of 16–42 mm, ≥ 20 mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate iliac/femoral access, ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16–42 mm. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials; patients who have a condition that threatens to infect the graft. Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. ^{Rx only}

Products listed may not be available in all markets.

GORE, Together, improving life, TAG and designs are trademarks of W. L. Gore & Associates, Inc.
© 2024 W. L. Gore & Associates, Inc. 24AR1002-EN AUGUST 2024

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 67332882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

